

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 February 2020 (06.02.2020)



(10) International Publication Number
WO 2020/025564 A1

(51) International Patent Classification:
C07K 16/30 (2006.01) C07K 16/40 (2006.01)

(21) International Application Number:
PCT/EP2019/070407

(22) International Filing Date:
30 July 2019 (30.07.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
18186591.6 31 July 2018 (31.07.2018) EP

(71) Applicant: **HEIDELBERG PHARMA RESEARCH GMBH** [DE/DE]; Schriesheimer Strasse 101, 68526 Ladenburg (DE).

(72) Inventors: **HECHLER, Torsten**; c/o Schriesheimer Strasse 101, 68526 Ladenburg (DE). **PAHL, Andreas**; c/o Schriesheimer Strasse 101, 68526 Ladenburg (DE).

(74) Agent: **MICHALSKI HÜTTERMANN & PARTNER, PATENTANWÄLTE MBB**; Speditionstr. 21, 40221 Düsseldorf (DE).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: HUMANIZED ANTIBODIES AGAINST PSMA




FIG. 1

(57) Abstract: The present application relates to humanized and/or deimmunized antibodies, antibody fragments or antibody derivatives that bind to Prostate Specific Membrane Antigen (PSMA) and methods for using said antibodies, antibody fragments or antibody derivatives in the treatment of prostate cancer and other neoplastic as well as neurological diseases.

[Continued on next page]



WO 2020/025564 A1

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*